An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer

The rs6983267-containing enhancer demonstrates distinct temporal regulatory abilities. Representative G (risk, top) and T (non-risk, bottom) transgenics are shown at a series of developmental time points. (A) E14.5 transgenic embryos exhibit beta-galactosidase expression in the genital tubercle and limbs, with no apparent allele-specific enhancer activity. (GT) Genital tubercle. (B,C) Allele-specific regulatory ability is visible in neonatal P0 pups (B) and P21 adolescent mice (C), with in vivo prostate and coagulating gland beta-galactosidase expression qualitatively stronger in the risk allele (top) line than the non-risk variant (bottom). (CG) Coagulating gland, (P) prostate.